Results 101 to 110 of about 507,315 (208)

Soluble epoxide hydrolase inhibitor promotes the healing of oral ulcers

, 2023
Objective: Oral ulcers are a lesion in the oral mucosa that impacts chewing or drinking. Epoxyeicosatrienoic Acids (EETs) have enhanced angiogenic, regenerative, anti-inflammatory, and analgesic effects.
Gao, Lu, Jili Chen, Yue Lou, Li, Juanjuan, Lou, Yue, Juanjuan Li, Lu Gao, Zihan Wen, Wang, Fu, Fu Wang, Xiaojie Li, Wen, Zihan, Chen, Jili, Li, Xiaojie   +13 more
core   +1 more source

Soluble Epoxide Hydrolase Inhibition for Ocular Diseases: Vision for the Future

Frontiers in Pharmacology, 2019
Ocular diseases cause visual impairment and blindness, imposing a devastating impact on quality of life and a substantial societal economic burden. Many such diseases lack universally effective pharmacotherapies.
Bomina Park, Bomina Park, Timothy W. Corson, Timothy W. Corson, Timothy W. Corson   +4 more
doaj   +1 more source

Deletion of soluble epoxide hydrolase attenuates mice Hyperoxic acute lung injury

BMC Anesthesiology, 2018
Background Recent studies reported that soluble epoxide hydrolase (sEH) plays an important role in lung diseases. However, the role of sEH in hyperoxia-induced ALI is unclear.
Li-Ping Liu, Bin Li, Tian-Kui Shuai, Lei Zhu, Yu-Min Li   +4 more
doaj   +1 more source

Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase

, 2007
Cyclooxygenase and lipoxygenase metabolism of arachidonic acid produces compounds important in cardiovascular control. Further, arachidonic acid can be metabolised by cytochrome p450 to produce epoxyeicosatrienoic acids (EETs).
Hammock, Bruce O., Hoey, Andrew, Brown, Lindsay, Morisseau, Christophe, Loch, David   +4 more
core  

Deficiency of Soluble Epoxide Hydrolase Protects Cardiac Function Impaired by LPS-Induced Acute Inflammation

Frontiers in Pharmacology, 2019
Lipopolysaccharide (LPS) is a bacterial wall endotoxin producing many pathophysiological conditions including myocardial inflammation leading to cardiotoxicity.
Victor Samokhvalov, K. Lockhart Jamieson, Ahmed M. Darwesh, Hedieh Keshavarz-Bahaghighat, Tim Y. T. Lee, Matthew Edin, Fred Lih, Darryl C. Zeldin, John M. Seubert, John M. Seubert   +9 more
doaj   +1 more source

Soluble epoxide hydrolase drives neurovascular dysfunction in a model of amyloidosis

Recent advances in anti-amyloid therapies for Alzheimer’s disease have been promising, but they have also highlighted critical challenges, including increased vascular complications, such as amyloid-related imaging abnormalities.
De Biasi, E., Junek , S., Acker-Palmer, A., Murphy, D., Hu, J., Müller, O., Fleming, I., Günther, S., Nilsson, P., Offermanns, S., Breunig, P., Candlish, M., Bohnstaedt, C., Herms, J., Hefendehl, J., Sauerland, C., Kawase, H., Hille, S., Neubauer, A., Neher, J., Hammock, B., Peguera, B., Underhill, T.   +22 more
core   +1 more source

Soluble epoxide hydrolase inhibition decreases reperfusion injury after focal cerebral ischemia

Scientific Reports, 2018
Epoxyeicosatrienoic acids (EETs) are produced by cytochrome P450 epoxygenases from arachidonic acid, and their rapid metabolism is mainly through soluble epoxide hydrolase (sEH).
Ranran Tu, Jillian Armstrong, Kin Sing Stephen Lee, Bruce D. Hammock, Adam Sapirstein, Raymond C. Koehler   +5 more
doaj   +1 more source

Enzyme inhibition kinetics of MMU on human soluble epoxide hydrolase.

, 2015
Enzyme kinetic analysis was performed on recombinant human soluble epoxide hydrolase (2 nM) using [3H] t-DPPO as a substrate. For each substrate concentration (4.0–30.0 μM), the velocity was plotted as a function of inhibitor concentration (0–1000 nM ...
Maximilienne Nyegue (690549), Bruce D. Hammock (65754), Shizuo G. Kamita (192776), Christophe Morisseau (362750), Gina R. De Nicola (690548), Bora Inceoglu (495917), Seiya Kitamura (690547)   +6 more
core   +1 more source

Discovery of soluble epoxide hydrolase inhibitors from natural products

, 2014
With the goal of developing soluble epoxide hydrolase (sEH) inhibitors with novel chemical structures, the sEH inhibitory activities of 30 natural compounds were evaluated using both a fluorescent substrate, 3-phenyl-cyano(6-methoxy-2-naphthalenyl)methyl
G H Lee, Soo Jin Oh, J Y Lee, J Y Ma, Y H Kim, S K Kim, S Y Lee   +6 more
core   +1 more source

Editorial: Clinical Paths for Soluble Epoxide Hydrolase Inhibitors

Frontiers in Pharmacology, 2020
John D. Imig, Christophe Morisseau
doaj   +1 more source